Given Imaging has purchased SmartPill’s single-use non-imaging capsule, designed for evaluating motility disorders such as gastroparesis and constipation, for $6m.
The FDA-approved and CE-marked wireless GI monitoring system features a data recorder that downloads the collected data, including pH rate, gastric emptying and total GI (stomach, small bowel and colon) transit times, as well as pressure and temperature within the GI tract.
The ingested capsule is excreted naturally from the body, usually within a day or two, according to the company.
Once the capsule has passed from the body, the patient returns the data recorder to the physician, who then uses the company’s MotiliGI software to analyse the data and provide test results in both graphical and report formats.
Massachusetts General Hospital Gastrointestinal Motility Laboratory director and Harvard Medical School instructor of medicine andgastroenterology unit assistant physician Dr Braden Kuo said SmartPill provides an ambulatory, patient-friendly and radiation-free alternative for patients suffering with challenging and painful symptoms of gastroparesis or chronic constipation.
“While SmartPill does not replace procedures like endoscopy and colonoscopy, it can replace multiple procedures used to assess gut transit requiring radiation exposure such as a timed Small Bowel Follow Through (SBFT), gastric emptying scintigraphy (GES) or sitzmarkers (ROM), which would be required to deliver the same clinical information,” Kuo said.
Given Imaging president and CEO Homi Shamir said incorporating SmartPill into its business will strengthen its value proposition to gastroenterologists.
“SmartPill is an excellent strategic fit with Given Imaging’s proprietary technology and extensive portfolio of GI diagnostic tools,” Shamir said.
“We anticipate that this acquisition will have an immediate contribution to our top-line results and will be accretive to our bottom-line by the end of 2014.”